Results from a phase 1 trial showed that a personalized mRNA neoantigen vaccine can stimulate an immune response in patients with pancreatic ductal adenocarcinoma.
Results from a phase 1 trial showed that a personalized mRNA neoantigen vaccine can stimulate an immune response in patients with pancreatic ductal adenocarcinoma.